Amgen is the world's biggest independent biotechnology developer, and was one of the original pioneers in that sector in the 1983 with the development of Epogen, a synthetic form of the hormone that controls red blood cell production. Unlike many of its biotech competitors it has so far avoided the temptation to be acquired by one of larger traditional pharma companies, but now ranks among them by annual revenues, partly as a result of several acquisitions of its own. It has built up a small but important drug portfolio, including nine billion-dollar blockbusters by 2015. These are led by the white blood cell stimulator Neulasta and its predecessor Neupogen (combined sales of $5.8bn), arthritis treatment Enbrel ($5.4bn in North America alone; Pfizer has rights elsewhere), Xgeva and Prolia for osteoporosis (combined sales of $2.7bn), Aranesp ($2.0bn), Epogen ($1.9bn) and Sensipar/Mipara for ($1.4bn). The company has a longstanding development partnership with Japanese drinks company Kirin, whose pharmaceuticals division was one of the original marketing partners for Epogen. In 2013, Amgen agreed to acquire smaller rival Onyx, developer of blood cancer treatment Kyprolis, for $10.4bn. Robert Bradway is CEO. Group revenues reached a record $21.7bn in 2015. The group was founded in 1980 as an experimental biotech famility under the name Applied Molecular Genetics. It adopted the abbreviated Amgen name in 1983. Adbrands does not currently profile this company but subscribers may access account assignments and contact information. The searchable account assignments database is available to full subscribers to Adbrands.net premium services. Click here to access Adbrands account assignments (subscribers only); or see here for information on how to subscribe.
Who handles advertising for Amgen? Find out more from the Adbrands Account Assignments database
Who are the competitors of Amgen? see Pharmaceutical Sector index
Capsule checked 21st July 2016
Recent stories from Adbrands Weekly Update:
Adbrands Weekly Update 22nd Mar 2018: Another week, another loss for struggling Wavemaker. Pharma group Amgen is to transfer its $350m US media account to Omnicom's Hearts & Science agency. The business was previously split between Wavemaker's predecessor MEC and Omnicom's specialist healthcare media unit SSCG, which will retain its share of B2B duties. Amgen's drugs include Enbrel, Neulasta and Neupogen.
Adbrands Weekly Update 29th Aug 2013: US pharmaceutical group Amgen, the global leader in hard-to-copy biotech drugs, announced a $10.4bn deal to acquire smaller rival Onyx, whose blood cancer treatment Kyprolis is forecast to top sales of $1bn by 2015. The deal will plug an expected hole in Amgen's product pipeline - its current top-sellers Neulasta and Neupogen will have passed their peak by 2015, while newer drugs in development may not be out of clinical trials.
Adbrands Company Profiles assess more than 1,000 leading advertisers, brands and agencies, and examine each company's business record, geographic strength and comparative performance within its chosen sector, including strengths and weaknesses, history, up-to-date news and top-line financial information. What else does the company do? How did it originate? What other brands does it own? How is it performing in the market? With what other businesses is it affiliated?
Adbrands Account Assignments is a database tracking account management for the world's leading brands and companies. In other words, which advertising agency handles which accounts in which countries. Fully searchable by brand, brandowner company or advertising agency, the database now contains more than 15,000 worldwide account assignments for over 4,000 leading brands.
New to the industry? See here for a brief summary of how the agency business is structured.
All rights reserved © Mind Advertising Ltd 1998-2018